



FILE UNICO

ITALIAN SUMMIT ON PRECISION MEDICINE

13-14 april 2026

VILLA AURELIA – Largo di Porta San Pancrazio 2 - Roma

Monday, 13 April 2026

09:00-09:05 5'	Opening remarks: Welcome and introduction	Giuseppe Curigliano, IT Paolo Marchetti, IT
09:05-11:15 130'	SESSION 1 Successes and Challenges in Precision Oncology	Chairs: Giampaolo Tortora, IT Andrea Botticelli, IT
	Opening Lecture	
20'	Learning from identification and use of biomarkers in precision oncology	Lillian L. Siu, Canada
10'	Q&A	All
20'	Learning from the evolution of master protocols for clinical trials in precision oncology	Vivek Subbiah, USA
10'	Q&A	All
20'	Strategies for the incorporation of biological correlative studies into Phase I clinical trials	Timothy A. Yap, USA
10'	Q&A	All
	Science Spotlight	
30'	Early cancer detection and cancer interception	Charles Swanton, UK
10'	Q&A	All
11:15-11:40	Coffee break	

Didactika srl

Piazza della Trasfigurazione 8/A - 00151 Roma

Tel: 06 94378432 e-mail: info@didactika.it

CF e P.IVA 12320201002 – REA RM-1365405



11:45-13:20 90'	SESSION 2 New strategies in Precision Oncology	Chair: Ruggero De Maria, IT Patricia Lorusso, USA
20'	Radioligand Therapeutics	Ken Hermann, DE
10'	Q&A	All
20'	Cell Therapy	Christian Blank, NE
10'	Q&A	All
20'	Vaccines	Paolo Ascierto, IT
10'	Q&A	All

13:15-14:20	Lunch
--------------------	--------------

14:20-16:00 100'	SESSION 3 Next generation ADCs	Chair: Sherene Loi, AU Paolo Ascierto, IT
30'	Novel ADC, immunoconjugates and bispecific antibodies	Sherene Loi, AU
10'	Q&A	All
20'	Applications of AI in ADC development	Antonio Marra, IT
10'	Q&A	All
	Science Spotlight	
30'	ADCs - The next generation: Novel constructs, bispecifics and payloads	Patricia Lorusso, USA
10'	Q&A	All

16:00-16:30	Coffee break
--------------------	---------------------



16:30-18:00 90'	SESSION 4 Hurdles in the regulatory and operational framework in Precision Oncology	Chairs: Nello Martini, IT Giuseppe Tonini, IT
20'	Challenges in precision oncology: Perspectives from an academia viewpoint	Giancarlo Pruneri, Italy
10'	Q&A	
20'	Challenges in precision oncology: Perspectives from a pharma viewpoint	Cristian Massaccesi, BMS, USA
10'	Q&A	
20'	Challenges in precision oncology: Perspectives from a biotech viewpoint	Alberto Bardelli, IT
10'	Q&A	
20'	Access to precision oncology globally	Raffaella Casolino, WHO
10'	Q&A	

18:00-19:00	Science Spotlight	
20'	Update on advanced Breast Cancer	Giuseppe Curigliano, IT
40'	Velocisuite – from target identification to human therapeutic antibodies, addressing limitations and bottlenecks	Teresa Ramirez Montagut

20:00	Dinner	
-------	---------------	--

Tuesday, 14 April 2026

09:00-10:30 90'	SESSION 5 Growing an ecosystem in precision oncology	Chairs: Massimo Di Maio, IT Cristian Massaccesi, USA
20'	Accelerating precision oncology in health care and research	Raffaella Casolino, WHO, CH
10'	Q&A	All
20'	Accelerating precision oncology through scientific societies	Cliff Hudis, USA
10'	Q&A	All
20'	Accelerating precision oncology through scientific journals	Thomas Powles, UK
10'	Q&A	All

Didactika srl

Piazza della Trasfigurazione 8/A - 00151 Roma

Tel: 06 94378432 e-mail: info@didactika.it

CF e P.IVA 12320201002 – REA RM-1365405



10:30-11:15	Science Spotlight	
	Adjuvant treatment in HR+ HER2 negative early breast cancer: how to tailor treatment Carmine De Angelis	
11:15-11:30	Coffee break	
11:30-12:10 40'	SESSION 6 ROME Award in Precision Oncology	Chairs: Andrea Botticelli, IT Giuseppe Curigliano, IT Paolo Marchetti, IT
30'	ESMO Frameworks in Precision Oncology	Fabrice Andr�, FR
10'	Q&A	All
12:10-13:50 100'	SESSION 7 Implementation of Precision Oncology in clinical practice	Chair: Robert Nistic�, AIFA Giuseppe Curigliano, IT
30'	Framework(s) to implement access to precision oncology	Christoph Benedikt Westphalen , DE
10'	Q&A	All
20'	How to build a precision oncology center: The model of the Institute for Personalized Cancer Therapy (IPCT)	Funda Meric Bernstam, USA
10'	Q&A	All
20'	How to interrogate data from large precision oncology dataset	Edoardo Crimini, IT Simone Scagnoli, IT
10'	Q&A	All
13:50-14:00 10'	Closing remarks	Giuseppe Curigliano, IT Paolo Marchetti, IT



RAZIONALE

Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this.

Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention. Personalized medicine promoters usually highlight its potential to combine a more effective health-care with costs containment, according to the following rules:

- monitoring of disease risks and more effective prevention;
- early intervention;
- selection of optimal therapy;
- reduction of trial-and-error prescribing and reduction of adverse drug reactions;
- exclusion of unnecessary drugs;
- therapeutic drug monitoring and disease progression/remission monitoring;
- increased patient compliance with therapy.

But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country. Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.

The aim of the meeting, where we are expecting about 150/200 participants from Italy and Europe, is to discuss with principal key opinion leader about the future prospective of precision medicine and precision oncology and the application in the real world.



FACULTY

ANDRE' FABRICE Villejuif-Paris (France) - Research Director Institut Gustave Roussy, Department of Medical Oncology

ASCIERTO PAOLO Naples (Italy) – Direttore Unità operativa di Melanoma Immunoterapia Oncologica e Terapie Innovative, Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli

BARDELLI ALBERTO Torino (ITALY) - IFOM Scientific Director, Principal Investigator Genomics of Cancer and Targeted Therapies, Professor Dept. Of Oncology University of Turin

BLANK CHRISTIAN Amsterdam (The Netherlands) - Group leader and clinical staff member, Netherlands Kancer Institut

BOTTICELLI ANDREA Rome (ITALY) - Medico oncologo presso Oncologia medica B Policlinico Umberto I, Roma

CASOLINO RAFFAELLA Geneva (Switzerland) Medico oncologo Ricercatore World Health Organization,

CRIMINI EDOARDO Milan (ITALY) Medical Oncologist at Department of Medical Oncology, European Institute of Oncology

CURIGLIANO GIUSEPPE Milan, (ITALY) Full Professor of Medical Oncology, Department of Oncology and Hemato-Oncology, University of Milano. Director Division of Early Drug Development for Innovative Therapies European Institute of Oncology, IRCCS

DE MARIA RUGGIERO Rome (ITALY) Professore Ordinario di Patologia Generale - Università Cattolica Sacro Cuore

HERMANN KEN Los Angeles (USA) – Full Professor of Nuclear Medicine at the Universitätsklinikum Essen; Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)

HUDIS CLIFFORD A. New York (USA) - Breast Medical Oncologist at Memorial Sloan Kettering Cancer Centre New York

LOI SHERENE Victoria (Australia) Consultant Medical Oncologist, Breast Unit; Head, Translational Breast Cancer Genomics and Therapeutics Lab (Loi Lab); Breast Stream Lead, Parkville Precinct Cancer Clinical Trials Unit at Peter MacCallum Cancer Center

LORUSSO PATRICIA New Haven/New York – (USA) Full Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics, Yale Cancer Center University"

MARCHETTI PAOLO Rome, (ITALY) - Head of Scientific Department Istituto Dermatologico dell'Immacolata IRCCS

MARRA ANTONIO Milan, (ITALY) Medical Oncologist at the Division of Early Drug Development for Innovative Therapies European Institute of Oncology, IRCC

MARTINI NELLO Rome, (ITALY) President of the Ricerca e Salute Foundation

MASSACESI CRISTIAN New York (USA) Chief Medical Officer (CMO) di Bristol Meyers Squibb

MERIC-BERNSTAM FUNDA Houston - Texas (USA) Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center



POWLES THOMAS London (UK) - Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's Hospital; Lead for Solid Tumour Research

PRUNERI GIANCARLO Milan (ITALY) "Head, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale Tumori, Milan. Full Professor in Pathology, University of Milan, School of Medicine Editor-in-Chief Tumori Journal"

SCAGNOLI SIMONE Rome (Italy) Dept. of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome

SIU LILLIAN Toronto (Canada) Senior Scientist, Princess Margaret Cancer Centre - Clinical Research Unit (CCRU)

SUBBIAH VIVEK Zurigo (Swiss) Chief, Early-Phase Drug Development at Sarah Cannon Research Institute

SWANTON CHARLES Deputy Clinical Director; Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute – London (United Kingdom)

TIMOTHY A. YAP Houston (USA) Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

TONINI GIUSEPPE Rome (Italy) Medical Oncology Unit, Fondazione Policlinico Universitario Campus Bio-medico

TORTORA GIAMPAOLO Rome (Italy) Medical Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli – IRCCS

WESTPHALEN CHRISTOPH BENEDIKT Munich, (Germany) Head "Molecular Diagnostics and Therapy Programme" and the "Molecular Tumour Board" at the University of Munich, Germany. Medical lead for early phase clinical trials in medical oncology

Responsabili scientifici: Giuseppe Curigliano, Andrea Botticelli

Sede di svolgimento: Villa Aurelia – Largo di Porta San Pancrazio 2 - Roma

Obiettivo formativo: Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura

Ore formative: 13

Destinatari: Medico Chirurgo; Psicologo, Biologo

Discipline di riferimento: tutte le discipline mediche, Psicologia, biologia

Dimensione territoriale: Nazionale

Provider ECM: Didactika S.r.l. – rif. Albo Nazionale n. 4795

Didactika srl

Piazza della Trasfigurazione 8/A - 00151 Roma

Tel: 06 94378432 e-mail: info@didactika.it

CF e P.IVA 12320201002 – REA RM-1365405